650 related articles for article (PubMed ID: 6744328)
1. Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival.
Coulson PB; Thornthwaite JT; Woolley TW; Sugarbaker EV; Seckinger D
Cancer Res; 1984 Sep; 44(9):4187-96. PubMed ID: 6744328
[TBL] [Abstract][Full Text] [Related]
2. [Flow cytophotometry parameters, hormone receptors and axillary lymph node status as prognostic factors in primary breast cancer].
Kaufmann M; Feichter GE; Nhila A; Klinga K; Abel U
Geburtshilfe Frauenheilkd; 1988 Oct; 48(10):705-9. PubMed ID: 3234702
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Yu H; Levesque MA; Clark GM; Diamandis EP
Clin Cancer Res; 1998 Jun; 4(6):1489-97. PubMed ID: 9626467
[TBL] [Abstract][Full Text] [Related]
4. Influence of cellular DNA content on disease-free survival of Stage II breast cancer patients.
Hedley DW; Rugg CA; Ng AB; Taylor IW
Cancer Res; 1984 Nov; 44(11):5395-8. PubMed ID: 6488193
[TBL] [Abstract][Full Text] [Related]
5. Differentiated DNA analysis in relation to steroid receptor status, grading, and staging in human breast cancer.
Meckenstock G; Bojar H; Hort W
Anticancer Res; 1987; 7(4B):749-54. PubMed ID: 3674762
[TBL] [Abstract][Full Text] [Related]
6. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
7. Indicators of prognosis in node-negative breast cancer.
Sigurdsson H; Baldetorp B; Borg A; Dalberg M; Fernö M; Killander D; Olsson H
N Engl J Med; 1990 Apr; 322(15):1045-53. PubMed ID: 2320064
[TBL] [Abstract][Full Text] [Related]
8. DNA ploidy and survival in breast cancer patients.
Cornelisse CJ; van de Velde CJ; Caspers RJ; Moolenaar AJ; Hermans J
Cytometry; 1987 Mar; 8(2):225-34. PubMed ID: 3582068
[TBL] [Abstract][Full Text] [Related]
9. Association of steroid hormone receptor content and flow cytometric DNA ploidy in endometrial carcinoma.
Grénman SE; Klemi P; Toikkanen S; Irjala K; Laippala P; Vähä-Eskeli K; Mäenpää J; Salmi T
Ann Chir Gynaecol Suppl; 1994; 208():10-4. PubMed ID: 8092757
[TBL] [Abstract][Full Text] [Related]
10. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.
Clark GM; Dressler LG; Owens MA; Pounds G; Oldaker T; McGuire WL
N Engl J Med; 1989 Mar; 320(10):627-33. PubMed ID: 2918874
[TBL] [Abstract][Full Text] [Related]
11. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
[TBL] [Abstract][Full Text] [Related]
12. Relationship of steroid receptor, cell kinetics, and clinical status in patients with breast cancer.
Kute TE; Muss HB; Anderson D; Crumb K; Miller B; Burns D; Dube LA
Cancer Res; 1981 Sep; 41(9 Pt 1):3524-9. PubMed ID: 7020931
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of DNA image cytometry in Libyan breast cancer.
Ermiah E; Abdalla F; Buhmeida A; Alshrad M; Salem N; Pyrhönen S; Collan Y
Oncology; 2012; 83(3):165-76. PubMed ID: 22906963
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.
Rosanelli GP; Steindorfer P; Wirnsberger GH; Klimpfinger M; Ratschek M; Puerstner P; Auner H; Berhold A
Anticancer Res; 1995; 15(2):581-6. PubMed ID: 7763041
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
[TBL] [Abstract][Full Text] [Related]
16. Ploidy, proliferative activity and estrogen receptor content in human breast cancer.
Raber MN; Barlogie B; Latreille J; Bedrossian C; Fritsche H; Blumenschein G
Cytometry; 1982 Jul; 3(1):36-41. PubMed ID: 7117052
[TBL] [Abstract][Full Text] [Related]
17. Hypoploidy defines patients with poor prognosis in breast cancer.
Chavez-Uribe E; Cameselle-Teijeiro J; Viñuela JE; Castro-Piñeiro C; Gude F; Forteza J; Puente-Domínguez JL
Oncol Rep; 2007 May; 17(5):1109-14. PubMed ID: 17390052
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
19. [Study of DNA content using a flow cytometry method and steroid hormone receptors in breast cancer].
Zubrikhina GN; Kuz'mina EV; Bassalyk LS; Murav'eva NI
Vopr Onkol; 1989; 35(10):1179-86. PubMed ID: 2596061
[TBL] [Abstract][Full Text] [Related]
20. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
